Press Releases March 29, 2026 10:00 AM

Autozi Internet Technology (Global) Ltd. Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities

Autozi Receives Nasdaq Notice for Minimum Market Value Deficiency with Compliance Deadline in September 2026

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
AZI

Autozi Internet Technology (Global) Ltd. announced that it received a notification from Nasdaq for failing to meet the minimum Market Value of Listed Securities of $50 million over the past 30 consecutive business days. The company has until September 21, 2026, to regain compliance or face potential delisting. The notification does not impact current trading.

Autozi Internet Technology (Global) Ltd. Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities
AZI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Autozi's Market Value of Listed Securities fell below Nasdaq's $50 million minimum requirement from February 10 to March 24, 2026.
  • Nasdaq granted a 180-day compliance period until September 21, 2026, to restore the market value or face delisting.
  • Autozi operates in China's automotive service and supply-chain technology sector, offering SaaS and integrated supply chain solutions.

BEIJING, March 29, 2026 (GLOBE NEWSWIRE) -- Autozi Internet Technology (Global) Ltd. (“Autozi” or the “Company”) (Nasdaq: AZI), one of China’s leading and fastest-growing lifecycle automotive service and supply-chain technology platforms, announced today that it has received a written notification (the "Notification Letter") from The Nasdaq Stock Market LLC (“Nasdaq”) dated March 25, 2026 indicating that the Company is not in compliance with the minimum Market Value of Listed Securities (“MVLS”) of US$50,000,000 set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq Global Market, as its MVLS for the 30 consecutive business days from February 10, 2026 to March 24, 2026 has failed to meet the minimum requirement. Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has a compliance period of 180 calendar days, or until September 21, 2026, to regain compliance. If at any time during this compliance period the Company’s MVLS closes at US$50,000,000 or more for a minimum of ten consecutive business days, Nasdaq will notify the Company that it has achieved compliance with the MVLS requirement, and the MVLS matter will be closed. In the event the Company does not regain compliance with Rule 5450(b)(2)(A) prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. This notification does not impact the listing and trading of the Company’s securities at this time.

About Autozi

Founded in 2010, Autozi is a fast-growing automotive service and technology platform in China. The company offers a broad portfolio of high-quality, cost-effective automotive products and services through online and offline channels nationwide. Using its advanced supply chain cloud platform and SaaS solutions, Autozi has built an integrated ecosystem that connects key stakeholders across the automotive industry, enhancing collaboration and efficiency throughout the supply chain.

Contact Information
Autozi Internet Technology (Global) Ltd.
Mr. Hui Zhang
Email: [email protected]


Risks

  • Failure to regain compliance by September 21, 2026, could lead to Nasdaq delisting, impacting stock liquidity and investor confidence.
  • The company's valuation concerns may signal financial or operational challenges, affecting its growth prospects in the automotive tech sector.
  • Regulatory and market pressures in the automotive service and supply-chain technology industries in China may add to company uncertainties.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026